Cecilia Arana Yi, MD
Hematology & Oncology · Scottsdale, AZNPI 1174752828
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Blueprint Medicines Corporation at 33.5% of the total. 2025 is the largest year on record at $19,624, 4.4 times the $4,440 reported in 2019.
Across 55 payments — averaging $791.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blueprint Medicines Corporation$15K
- E.r. Squibb & Sons, L.L.C.$9K
- Sanofi US Services Inc.$6K
- Jazz Pharmaceuticals Inc.$4K
- Bristol Myers Squibb$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- plus $5K from 8 others
Across 92 payments — averaging $4402.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$171K
- Incyte Corporation$68K
- Blueprint Medicines Corporation$63K
- Takeda Pharmaceuticals U.S.A., Inc.$28K
- Otsuka Pharmaceutical Co., Ltd.$24K
- Astrazeneca UK Limited$24K
- plus $27K from 4 others
What the payments were for
- Consulting fees$21,74150%
- Speaking & faculty fees$14,00832%
- Travel & lodging$6,08214%
- Food & beverage$1,7024%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blueprint Medicines Corporation | 17 | $14,574 |
| E.r. Squibb & Sons, L.L.C. | 4 | $8,543 |
| Sanofi US Services Inc. | 2 | $5,896 |
| Jazz Pharmaceuticals Inc. | 12 | $4,426 |
| Bristol Myers Squibb | 6 | $3,191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,310 |
| Adaptive Biotechnologies Corporation | 5 | $1,926 |
| Genentech USA, Inc. | 1 | $1,925 |
| Daiichi Sankyo Inc. | 1 | $289 |
| Astellas Pharma US Inc | 1 | $154 |
| Gilead | 2 | $137 |
| Sanofi | 1 | $120 |
| Astrazeneca UK Limited | 1 | $55 |
| Acrotech Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,558 in reported general payments places this provider in the 85th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AyvakitAvapritinib | 40 | $1,561,047 |
| JakafiRuxolitinib Phosphate | 36 | $610,566 |
| BesremiRopeginterferon Alfa-2b-Njft | 18 | $284,818 |
| IclusigPonatinib Hcl | 11 | $233,628 |
| TasignaNilotinib Hcl | 11 | $220,800 |
| PromactaEltrombopag Olamine | 11 | $213,440 |
| VonjoPacritinib Citrate | 12 | $142,568 |
| VenclextaVenetoclax | 32 | $120,231 |
| PegasysPeginterferon Alfa-2a | 14 | $57,641 |
| Imatinib Mesylate | 48 | $37,343 |
| Cyclosporine ModifiedCyclosporine, Modified | 16 | $5,011 |
| Cromolyn Sodium | 11 | $3,062 |
| Acyclovir | 84 | $1,004 |
| Fluconazole | 21 | $973 |
| Hydroxyurea | 48 | $866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Blueprint Medicines CorporationAyvakit | $14,574 | $1,561,04740 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $2,310 | $233,62811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Scottsdale
- Jeffrey SchriberScottsdale$715K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Yousef ZakhariaScottsdale$214K
- Thai HoScottsdale$190K
- Alan BryceScottsdale$157K
- Daniel AhnScottsdale$91K
- Brendan CurleyScottsdale$87K
- Alexander StewartScottsdale$76K
- Saurabh ChhabraScottsdale$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.